Citation Impact
Citing Papers
Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis
2016
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
2006
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma
2015
Hepatocellular carcinoma
2022 Standout
Hepatocellular Carcinoma
2019 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
2016
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Works of Mathieu Boulin being referenced
Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma
2011
Serum Gamma-Glutamyl-Transferase Independently Predicts Outcome After Transarterial Chemoembolization of Hepatocellular Carcinoma: External Validation
2011
Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma
2011
Impact économique de la chimioembolisation avec microsphères chargées dans le traitement du carcinome hépatocellulaire
2011
Improved stability of lipiodol–drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin
2015
[Thalidomide with or without dexamethasone for refractory multiple myeloma].
2003